A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2

Inoculation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing worldwide. However, the emergence of SARS-CoV-2 variants could cause immune evasion. We developed a bivalent nanoparticle vaccine that displays the receptor binding domains (RBDs) of the D614G and B.1.351 str...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Yaochang, Zhang, Xiantao, Chen, Ran, Li, Yuzhuang, Wu, Bolin, Li, Rong, Zou, Fan, Ma, Xiancai, Wang, Xuemei, Chen, Qier, Deng, Jieyi, Zhang, Yongli, Chen, Tao, Lin, Yingtong, Yan, Shumei, Zhang, Xu, Li, Congrong, Bu, Xiuqing, Peng, Yi, Ke, Changwen, Deng, Kai, Pan, Ting, He, Xin, Zhang, Yiwen, Zhang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. 2022
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695190/
https://www.ncbi.nlm.nih.gov/pubmed/34990583
http://dx.doi.org/10.1016/j.celrep.2021.110256
Descripción
Sumario:Inoculation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing worldwide. However, the emergence of SARS-CoV-2 variants could cause immune evasion. We developed a bivalent nanoparticle vaccine that displays the receptor binding domains (RBDs) of the D614G and B.1.351 strains. With a prime-boost or a single-dose strategy, this vaccine elicits a robust neutralizing antibody and full protection against infection with the authentic D614G or B.1.351 strain in human angiotensin-converting enzyme 2 transgene mice. Interestingly, 8 months after inoculation with the D614G-specific vaccine, a new boost with this bivalent vaccine potently elicits cross-neutralizing antibodies for SARS-CoV-2 variants in rhesus macaques. We suggest that the D614G/B.1.351 bivalent vaccine could be used as an initial single dose or a sequential enforcement dose to prevent infection with SARS-CoV-2 and its variants.

Ejemplares similares